> Detailanzeige

Mohrmann, Gerrit; Hengstler, Jan G.; Hofmann, Thomas G.; Endele, Sabine U.; Lee, Brendan; Stelzer, Christiane; Zabel, Bernhard; Brieger, Juergen; Hasenclever, Dirk; Tanner, Berno; Sagemueller, Jens; Sehouli, Jalid; Will, Hans; Winterpacht, Andreas

SPOC1, a novel PHD‐finger protein: Association with residual disease and survival in ovarian cancer

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: SPOC1, a novel PHD‐finger protein: Association with residual disease and survival in ovarian cancer
  • Beteiligte: Mohrmann, Gerrit; Hengstler, Jan G.; Hofmann, Thomas G.; Endele, Sabine U.; Lee, Brendan; Stelzer, Christiane; Zabel, Bernhard; Brieger, Juergen; Hasenclever, Dirk; Tanner, Berno; Sagemueller, Jens; Sehouli, Jalid; Will, Hans; Winterpacht, Andreas
  • Erschienen: Wiley, 2005
  • Erschienen in: International Journal of Cancer
  • Sprache: Englisch
  • DOI: 10.1002/ijc.20912
  • ISSN: 0020-7136; 1097-0215
  • Schlagwörter: Cancer Research ; Oncology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title><jats:p>We report the identification of a novel human gene (<jats:italic>SPOC1</jats:italic>) which encodes a protein with a PHD‐finger domain. The gene is located in chromosomal region 1p36.23, a region implicated in tumor development and progression. RNA <jats:italic>in situ</jats:italic> hybridization experiments showed strong <jats:italic>SPOC1</jats:italic> expression in some rapidly proliferating cell types, such as spermatogonia, but not in nonpro‐liferating mature spermatocytes. In addition, high <jats:italic>SPOC1</jats:italic> mRNA expression was observed in several ovarian cancer cell lines. This prompted us to systematically examine <jats:italic>SPOC1</jats:italic> expression in ovarian cancer in relation to prognosis. <jats:italic>SPOC1</jats:italic> mRNA expression was quantified in tumor tissue of 103 patients with epithelial ovarian cancer. Interestingly, <jats:italic>SPOC1</jats:italic> was associated with residual disease, whereby patients with unresectable tumors showed higher levels compared to patients without residual tumor tissue after surgery (<jats:italic>p</jats:italic> = 0.029). The univariable proportional hazards model showed an association between <jats:italic>SPOC1</jats:italic> expression and survival (<jats:italic>p</jats:italic> = 0.043, relative risk = 1.535). Median survival time was 1,596 days for patients with low <jats:italic>SPOC1</jats:italic> expression <jats:italic>vs.</jats:italic> only 347 days for patients with high expression, using Kaplan‐Meier analysis. However, <jats:italic>SPOC1</jats:italic> was not associated with survival when multivariable analysis was adjusted for residual disease. This can be explained by the correlation between residual disease and <jats:italic>SPOC1</jats:italic> expression. In conclusion, <jats:italic>SPOC1</jats:italic> is a novel PHD‐finger protein showing strong expression in spermatogonia and ovarian cancer cells. <jats:italic>SPOC1</jats:italic> overexpression was associated with unresectable carcinomas and shorter survival in ovarian cancer. © 2005 Wiley‐Liss, Inc.</jats:p>
  • Zugangsstatus: Freier Zugang